プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Marie W.に依頼

United States

Biomarker scientist with 10+ years supporting clinical trials

プロフィール概要

I have extensive experience developing preclinical biomarker assays on a variety of assay platforms and managing their execution during early stage clinical trials. I have co-ordinated patient sample tracking and submission to various external vendors and managed communication with these vendors. I have experience with biomarker data analysis and presentation including data types such as mutation, ctDNA, nanostring, ELISA, ddPCR, MSD and protein simple. I have published extensively in the field of biomarker development.

専門分野

• ★ Biomarkers
• ☆ Cell Signaling Pathways
• ☆ Drug Development

サービス

• Writing
• Research
• Consulting
• Data & AI

Writing Technical Writing

Research Market Research, Systematic Literature Review

Consulting Scientific and Technical Consulting

Data & AI Statistical Analysis, Data Visualization

職務経験

Associate Director

Ideaya Biosciences

1月 2019 - 1月 2020

Principal scientific researcher

Genentech / Roche

1月 2010 - 1月 2019

学歴

PhD in Cell and molecular biology

University of East Anglia, Norwich

9月 1998 - 3月 2002

認定資格

• 認定資格の詳細は未入力です。

出版物

JOURNAL ARTICLE

(2020). Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer . Cancer immunology research.

(2019). A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors . Clinical cancer research : an official journal of the American Association for Cancer Research.

(2019). CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms . Cancer research.

(2018). Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology . NPJ precision oncology.

(2018). A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types . NPJ precision oncology.

(2017). Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors . PloS one.

(2016). A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia . Leukemia.

(2014). Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition . Genes & cancer.

(2013). Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068 . Clinical cancer research : an official journal of the American Association for Cancer Research.

(2009). R-Spondin1 protects mice from chemotherapy or radiation-induced oral mucositis through the canonical Wnt/beta-catenin pathway . Proceedings of the National Academy of Sciences of the United States of America.

(2008). R-Spondin family members regulate the Wnt pathway by a common mechanism . Molecular biology of the cell.

(2007). R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6 . Proceedings of the National Academy of Sciences of the United States of America.

(2007). TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA . The EMBO journal.

(2003). The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1 . The Journal of biological chemistry.

(2002). Cryptic promoter activity of pBLCAT3 induced by overexpression of AP1 factors . BioTechniques.

(1999). In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6 . British journal of cancer.